{
  "compound": "CBD isolate",
  "condition": "MULTIPLE_SCLEROSIS",
  "effect_size": "Medium (Cohen's d = 0.58)",
  "study_type": "RCT",
  "source": "NORML:MS_RCT_007",
  "participants": "106 MS patients with resistant spasticity",
  "year": 2019,
  "notes": "Cannabidiol for MS Spasticity: CBD-Only Formulation Trial",
  "confidence": "medium",
  "abstract": "CBD: 34% responders (NRS \u226530% improvement) vs Placebo: 18%; MAS improved 22% vs 11%"
}